Tradjenta Approved for Type 2 Diabetes

Should not be used by type 1 diabetes patients

MONDAY, May 2 (HealthDay News) -- Tradjenta (linagliptin) tablets, combined with diet and exercise, have been approved by the U.S. Food and Drug Administration to control blood sugar in people with type 2 diabetes, the agency said Monday.

Type 2 diabetes affects up to 95 percent of the estimated 24 million people with diabetes in the United States, the FDA said.

Tradjenta boosts hormones that stimulate the release of insulin after a person eats. The drug was evaluated in clinical trials involving 3,800 people with type 2 diabetes. The most common adverse reactions reported included upper respiratory infection, stuffy nose, sore throat, muscle pain and headache.

Tradjenta should not be used by people with type 1 diabetes or by those who have above-normal levels of ketones in their blood or urine, the agency advised.

The drug is co-marketed by Ridgefield, Conn.-based Boehringer Ingelheim Pharmaceuticals and Indianapolis-based Eli Lilly and Co.

More information

To learn more about type 2 diabetes, visit the National Diabetes Information Clearinghouse.

Copyright © 2011 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

What internal motivators drive RNs to pursue a BSN?
Nursing2014 , October 2014
Free access will expire on November 24, 2014.


Breast Cancer Risk Assessment in Primary Care
MCN, The American Journal of Maternal/Child Nursing, September/October 2014
Free access will expire on November 10, 2014.


Nurses spurring innovation
Nursing Management, October 2014
Free access will expire on November 10, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events